Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/338214
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampOliveira, Mariana Gonçalves de-
dc.contributor.authorunicampBertollotto, Gabriela Maria-
dc.contributor.authorunicampCândido, Tuany Zambroti-
dc.contributor.authorunicampKiguti, Luiz Ricardo de Almeida-
dc.contributor.authorunicampAntunes, Edson-
dc.contributor.authorunicampDe Nucci, Gilberto-
dc.contributor.authorunicampMónica, Fabíola Zakia-
dc.typeArtigopt_BR
dc.titleMirabegron elicits rat corpus cavernosum relaxation and increases in vivo erectile responsept_BR
dc.contributor.authorde Oliveira, Mariana G.-
dc.contributor.authorRojas-Moscoso, Julio Alejandro-
dc.contributor.authorBertollotto, Gabriela M.-
dc.contributor.authorCandido, Tuany Z.-
dc.contributor.authorKiguti, Luiz Ricardo de A.-
dc.contributor.authorPupo, Andre S.-
dc.contributor.authorAntunes, Edson-
dc.contributor.authorDe Nucci, Gilberto-
dc.contributor.authorMonica, Fabiola Z.-
dc.subjectMirabegronpt_BR
dc.subjectDisfunção erétilpt_BR
dc.subject.otherlanguageMirabegronpt_BR
dc.subject.otherlanguageErectile dysfunctionpt_BR
dc.description.abstractMirabegron is the first beta 3-adrenoceptor agonist approved on the market and may offer beneficial pharmacological action in patients with overactive bladder and erectile dysfunction. Here, we further investigate the mechanisms by which mirabegron induces rat corpus cavernosum (CC) relaxation. Adult male Wistar rats were used. The CC were isolated for in vitro functional assays and beta-adrenoceptors subtypes mRNA expression evaluation. Animals were treated orally with mirabegron (30 mg/kg, 3 h), tadalafil (10 mg/kg, 3 h) or both for intracavernous pressure (ICP). Intracellular levels of cAMP and cGMP were also determined. The beta 1-, beta 2- and beta 3-adrenoceptors subtypes were expressed in rat CC. Mirabegron produced concentration-dependent CC relaxations that were unaffected by the beta 1-, beta 2- or beta 3-adrenoceptor antagonists atenolol (1 mu M), ICI-118,551 (1 mu M) and L748,337 (10 mu M), respectively. Mirabegron-induced relaxations were not affected by the phosphodiesterase type 4 inhibitor, rolipram, or the adenylyl cyclase selective inhibitor, SQ 22,536. Potassium channel-or calcium influx-blockade are not involved in mirabegron-induced relaxations. In contrast, mirabegron produced rightward shifts in the contractile response induced by the alpha 1-adrenoceptor agonist, phenylephrine. Finally, cavernous nerve stimulation caused frequency-dependent ICP increases, which were significantly increased in rats treated with mirabegron in a similar degree of tadalafil-treated rat, without promoting a significant cAMP or cGMP accumulation. Together, our results demonstrate that mirabegron induced CC relaxation through alpha 1-adrenoceptor blockade. Care should be taken to translate the effect of mirabegron into the clinic, especially when using rat as an animal model of erectile dysfunction.pt_BR
dc.relation.ispartofEuropean journal of pharmacologypt_BR
dc.relation.ispartofabbreviationEur. j. pharmacol.pt_BR
dc.publisher.cityAmsterdampt_BR
dc.publisher.countryHolandapt_BR
dc.publisherElsevierpt_BR
dc.date.issued2019-
dc.date.monthofcirculationSep.pt_BR
dc.language.isoengpt_BR
dc.description.volume858pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn0014-2999pt_BR
dc.identifier.eissn1879-0712pt_BR
dc.identifier.doi10.1016/j.ejphar.2019.172447pt_BR
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0014299919303991pt_BR
dc.description.sponsorshipFUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO - FAPESPpt_BR
dc.description.sponsordocumentnumber2013/13907-4; 2017/15175-1; 2018/09765-3pt_BR
dc.date.available2020-03-31T12:50:28Z-
dc.date.accessioned2020-03-31T12:50:28Z-
dc.description.provenanceSubmitted by Bruna Maria Campos da Cunha (bcampos@unicamp.br) on 2020-03-31T12:50:28Z No. of bitstreams: 0. Added 1 bitstream(s) on 2020-07-20T14:18:42Z : No. of bitstreams: 1 000477699100029.pdf: 1258560 bytes, checksum: c6bdfd8f43b81c314ee7407d65251889 (MD5)en
dc.description.provenanceMade available in DSpace on 2020-03-31T12:50:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/338214-
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.departmentSem informaçãopt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordIntracavernous pressurept_BR
dc.subject.keywordTadalafilpt_BR
dc.subject.keywordCyclic GMPpt_BR
dc.subject.keywordCyclic AMPpt_BR
dc.identifier.source000477699100029pt_BR
dc.creator.orcidorcid.org/0000-0003-2226-2530pt_BR
dc.creator.orcidSem informaçãopt_BR
dc.creator.orcidorcid.org/0000-0001-5054-1911pt_BR
dc.creator.orcidorcid.org/0000-0002-7609-9313pt_BR
dc.creator.orcidorcid.org/0000-0003-2201-8247pt_BR
dc.creator.orcidorcid.org/0000-0002-4346-7941pt_BR
dc.creator.orcidorcid.org/0000-0002-8449-6677pt_BR
dc.type.formArtigopt_BR
dc.identifier.articleid172447pt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000477699100029.pdf1.23 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.